Current Problems in Cardiology最新文献

Corrigendum to "Clinical profile and cardiovascular events in patients with atrial fibrillation and hematologic malignancies with recent initiation of targeted therapy: real-life data from CANAC-FA registry" [Current Problems in Cardiology 50(2025):102974]. “最近开始靶向治疗的心房颤动和血液恶性肿瘤患者的临床概况和心血管事件：来自CANAC-FA登记的真实数据”[Current Problems in Cardiology 50(2025):102974]的更正。

IF 3.3 3区医学

Current Problems in Cardiology Pub Date : 2025-07-31 DOI: 10.1016/j.cpcardiol.2025.103131

Alberto Piserra López Fernández de Heredia, Martín Ruiz Ortiz, Javier Torres Llergo, Magdalena Carrillo Bailen, María Sánchez de Castro, Margarita Fernández de la Mata, Arancha Díaz Exposito, Alejandro I Pérez Cabeza, Mónica Delgado Ortega, María García Fortes, Inmaculada Fernández Valenzuela, Marinela Chaparro Muñoz, Alicia Rodríguez Fernández, Ana María Rodríguez Almodóvar, Inara Alarcón de la Lastra Cubiles, Fátima Esteban Martínez, Francisco Javier Capote Huelva, José Javier Sánchez Fernandez, Dolores Mesa Rubio

引用次数: 0

Corrigendum to "New severity criteria for tricuspid regurgitation in a broad population of "real life" patients: prevalence and prognostic impact" [Current Problems in Cardiology 49(2024) 102211]. “在广泛的“现实生活”患者人群中三尖瓣反流的新严重程度标准：患病率和预后影响”[心脏病学当前问题49(2024)102211]的勘误表。

IF 3.3 3区医学

Current Problems in Cardiology Pub Date : 2025-07-31 DOI: 10.1016/j.cpcardiol.2025.103130

Ana Fernández Ruiz, Martín Ruiz Ortiz, Consuelo Fernández-Avilés Irache, Ana María Rodríguez Almodóvar, Mónica Delgado Ortega, Fátima Esteban Martínez, Adriana Resúa Collazo, Gloria Heredia Campos, Manuel Pan Álvarez-Ossorio, Dolores Mesa Rubio

引用次数: 0

Editor’s Message 编辑器’的消息

IF 3 3区医学

Current Problems in Cardiology Pub Date : 2025-07-28 DOI: 10.1016/S0146-2806(25)00161-6

引用次数: 0

Title Page 标题页

IF 3 3区医学

Current Problems in Cardiology Pub Date : 2025-07-28 DOI: 10.1016/S0146-2806(25)00155-0

引用次数: 0

Information for Readers 读者资讯

IF 3 3区医学

Current Problems in Cardiology Pub Date : 2025-07-28 DOI: 10.1016/S0146-2806(25)00156-2

引用次数: 0

Guidelines for Authors 作者指南

IF 3 3区医学

Current Problems in Cardiology Pub Date : 2025-07-28 DOI: 10.1016/S0146-2806(25)00162-8

引用次数: 0

Erratum to "Selexipag in Patients with Pulmonary Hypertension: A Systematic Review and Meta-Analysis of Randomized Controlled Trials" [Current Problems in Cardiology 48(2023) 101466]. “Selexipag在肺动脉高压患者中的应用：随机对照试验的系统评价和荟萃分析”[contemporary Problems in Cardiology] 48(2023) 101466]。

IF 3.3 3区医学

Current Problems in Cardiology Pub Date : 2025-07-26 DOI: 10.1016/j.cpcardiol.2025.103127

Jinlv Qin, Guizuo Wang, Dong Han

引用次数: 0

Tafamidis: A game changer in transthyretin cardiomyopathy? A systematic review and meta-analysis of safety and efficacy Tafamidis：促甲状腺素型心肌病的游戏规则改变者？安全性和有效性的系统评价和荟萃分析。

IF 3 3区医学

Current Problems in Cardiology Pub Date : 2025-07-18 DOI: 10.1016/j.cpcardiol.2025.103129

Bilal Hussain MD , Sanchit Duhan MBBS , Bansari Patel MD , Yu-Chun Chang MS3 PhD , Mohammad Hamza MD , Maria Najam MD , Mustafa Sajjad Cheema MD , Mubashar Karamat MD , Junaid Mir MD , Bijeta Keisham MD , M. Chadi Alraies MD , Yasar Sattar MD

{"title":"Tafamidis: A game changer in transthyretin cardiomyopathy? A systematic review and meta-analysis of safety and efficacy","authors":"Bilal Hussain MD , Sanchit Duhan MBBS , Bansari Patel MD , Yu-Chun Chang MS3 PhD , Mohammad Hamza MD , Maria Najam MD , Mustafa Sajjad Cheema MD , Mubashar Karamat MD , Junaid Mir MD , Bijeta Keisham MD , M. Chadi Alraies MD , Yasar Sattar MD","doi":"10.1016/j.cpcardiol.2025.103129","DOIUrl":"10.1016/j.cpcardiol.2025.103129","url":null,"abstract":"<div><h3>Purpose</h3><div>Tafamidis was FDA-approved for Transthyretin cardiomyopathy (ATTR-CM) due to its demonstrated reduction in mortality and hospitalizations.</div></div><div><h3>Methods</h3><div>976 studies from PubMed and Embase were screened. Seven studies were included that compared tafamidis treatment with no tafamidis for ATTR-CM. The mantel-Haenszel method was used for binary outcomes, and Hedges’ g was used for continuous outcomes.</div></div><div><h3>Results</h3><div>Tafamidis was associated with decreased odds of mortality (OR 0.55, 95 % CI 0.42-0.73, I<sup>2</sup>=41 %, p<0.0001) and reduced CHF exacerbations (OR 0.71, 95 % CI 0.51-0.99, I<sup>2</sup>= 0 %, p= 0.04). While, CHF related hospitalizations (OR 0.35, 95 % CI 0.07-1.67, I2= 87 %, p= 0.19), atrial arrhythmias (OR 0.98, 95 % CI 0.67-1.42, I<sup>2</sup>= 0 %, p= 0.9), change in left ventricular ejection fraction (SMD 0.87, 95 % CI -0.37-2.11, I<sup>2</sup>=98 %, p= 0.17), left ventricular end-diastolic diameter from baseline (SMD -0.12, 95 % CI -0.41-0.18, I<sup>2</sup>= 0 %, p= 0.4), interventricular septal thickness from baseline (SMD -0.7, 95 % CI -1.57-0.17, I<sup>2</sup>= 96 %, p= 0.11) were not statistically different for tafamidis compared to no tafamidis for ATTR-CM.</div></div><div><h3>Conclusion</h3><div>Tafamidis treatment in ATTR-CM is associated with reduced all-cause mortality and a lower incidence of CHF exacerbations. These observations are consistent with the ATTRACT trial, which supports the efficacy of tafamidis in treating ATTR-CM.</div></div>","PeriodicalId":51006,"journal":{"name":"Current Problems in Cardiology","volume":"50 9","pages":"Article 103129"},"PeriodicalIF":3.0,"publicationDate":"2025-07-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144676408","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Heart failure with microvascular dysfunction: Insights from a propensity-matched analysis of diabetic retinopathy in heart failure with reduced ejection fraction 心力衰竭伴微血管功能障碍：来自糖尿病视网膜病变伴射血分数降低心力衰竭倾向匹配分析的见解。

IF 3 3区医学

Current Problems in Cardiology Pub Date : 2025-07-18 DOI: 10.1016/j.cpcardiol.2025.103128

Silvio Nunes Augusto Jr , Rochell Issa MD , David Kaelber MD PhD MPH , W.H. Wilson Tang MD

{"title":"Heart failure with microvascular dysfunction: Insights from a propensity-matched analysis of diabetic retinopathy in heart failure with reduced ejection fraction","authors":"Silvio Nunes Augusto Jr , Rochell Issa MD , David Kaelber MD PhD MPH , W.H. Wilson Tang MD","doi":"10.1016/j.cpcardiol.2025.103128","DOIUrl":"10.1016/j.cpcardiol.2025.103128","url":null,"abstract":"<div><h3>Background</h3><div>Diabetic retinopathy, a microvascular complication of diabetes, is a significant marker of systemic vascular damage, which has been linked to increased cardio-renal disease risks. This study investigates the impact of diabetic retinopathy on all-cause mortality and adverse cardiovascular and renal outcomes in patients with established heart failure with reduced ejection fraction (HFrEF) using real-world data.</div></div><div><h3>Methods</h3><div>Using data from January 1, 2012, to December 31, 2021, we conducted a propensity-matched analysis of two cohorts of patients with HFrEF and diabetes without chronic kidney disease (CKD, estimated glomerular filtration rate >60 mL/min/1.73 m²), differentiated by the presence or absence of diabetic retinopathy diagnosis in the TriNetX platform. The primary outcome was all-cause mortality, with secondary outcomes including acute HF, CKD progression, major adverse cardiovascular events, stroke, in-patient hospitalizations, venous thromboembolism (VTE), and peripheral arterial disease (PAD).</div></div><div><h3>Results</h3><div>Following propensity score matching across demographics and clinical variables, each cohort included 15,218 patients. Acute HF was more common in the retinopathy vs non-retinopathy cohort (HR: 1.13, 95 % CI: 1.06–1.20). Results also showed significant increased risks for CKD progression (HR: 1.39, 95 % CI: 1.30–1.50), stroke (HR: 1.18, 95 % CI: 1.08–1.28), as well as PAD (HR: 1.58, 95 % CI: 1.42–1.76) for patients with diabetic retinopathy.</div></div><div><h3>Conclusion</h3><div>Diabetic retinopathy is associated with an increased risk of adverse cardio-renal outcomes in patients with established HFrEF.</div></div>","PeriodicalId":51006,"journal":{"name":"Current Problems in Cardiology","volume":"50 10","pages":"Article 103128"},"PeriodicalIF":3.0,"publicationDate":"2025-07-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144676407","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Effect of Implementation of Follow-Up Care Model on Self-Management in Patient with Chronic Heart Failure Disease. 实施随访护理模式对慢性心力衰竭患者自我管理的影响

IF 3 3区医学

Current Problems in Cardiology Pub Date : 2025-07-01 DOI: 10.1016/j.cpcardiol.2025.103120

Mohammed Khanjary, Shokoh Varaei, Haitham Ibrahim Faris

引用次数: 0